ArticleScientific reports2020
Serum adropin levels are reduced in patients with inflammatory bowel diseases.
Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 32 citations in OpenAlex.
- Gingival crevicular fluid asprosin, adropin, and irisin hormone levels in the different periodontal status.Clinical oral investigations · 2026Article
- Decreasing Serum Adropin Levels in Patients With Systemic Lupus Erythematosus: A Case-Control Study.Health science reports · 2026Article
- Clinical efficacy analysis of acupuncture combined with anti-tumor necrosis factor treatment for spleen and kidney yang deficiency type ulcerative colitis.Frontiers in medicine · 2026Article
- A Potential Role of Adropin in Inflammatory Rheumatic Diseases-What Do We Know So Far?Biomedicines · 2025Review
- Measurement of serum adropin levels in chronic renal failure patients receiving routine hemodialysis treatment.Medicine · 2025Observational
- Adropin: a key player in immune cell homeostasis and regulation of inflammation in several diseases.Frontiers in immunology · 2025Review
- The Comparison of Irisin, Subfatin, and Adropin in Normal-Weight and Obese Polycystic Ovary Syndrome Patients.Iranian journal of medical sciences · 2024Article
- Growth differentiation factor-15 serum concentrations reflect disease severity and anemia in patients with inflammatory bowel disease.World journal of gastroenterology · 2024Article
- [Research advances on B-cell activating factor and its targeted agents in inflammatory bowel disease].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2024Review
- Clinical Significance of Adropin and Afamin in Evaluating Renal Function and Cardiovascular Health in the Presence of CKD-MBD Biomarkers in Chronic Kidney Disease.Diagnostics (Basel, Switzerland) · 2023Article
- Pathophysiology of Inflammatory Bowel Disease: Innate Immune System.International journal of molecular sciences · 2023Review
- Association of serum lipids with inflammatory bowel disease: a systematic review and meta-analysis.Frontiers in medicine · 2023Review
- Elastic band resistance training increases adropin and ameliorates some cardiometabolic risk factors in elderly women: A quasi-experimental study.BMC sports science, medicine & rehabilitation · 2022Article
- Serum Adropin Levels in Patients with Rheumatoid Arthritis.Life (Basel, Switzerland) · 2022Article
- Role of B-Cell Activating Factor (BAFF) in Inflammatory Bowel Disease.Diagnostics (Basel, Switzerland) · 2021Review
- Role of Adropin in Cardiometabolic Disorders: From Pathophysiological Mechanisms to Therapeutic Target.Biomedicines · 2021Review
- Urotensin II levels in patients with inflammatory bowel disease.World journal of gastroenterology · 2021Article
- Effects of Wine Components in Inflammatory Bowel Diseases.Molecules (Basel, Switzerland) · 2021Review
- Adropin Serum Levels in Patients with Primary Sjögren's Syndrome.Biomolecules · 2021Article
- Serum Adropin Levels in Patients on Hemodialysis.Life (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adropin is a novel peptide mostly associated with energy homeostasis and vascular protection. To our knowledge, there are no studies that investigated its relationship with inflammatory bowel diseases (IBD). The aim of this study was to compare serum adropin levels between 55 patients with IBD (30 Ulcerative colitis (UC) patients, 25 Crohn's disease (CD) patients) and 50 age/gender matched controls. Furthermore, we explored adropin correlations with IBD severity scores, hsCRP, fecal calprotectin, fasting glucose and insulin levels. Serum adropin levels were significantly lower in patients with IBD in comparison with the control group (2.89 ± 0.94 vs 3.37 ± 0.60 ng/mL, P = 0.002), while there was no significant difference in comparison of UC patients with CD patients (P = 0.585). Furthermore, there was a negative correlation between adropin and fecal calprotectin (r = -0.303, P = 0.025), whereas in the total study population, we found a significant negative correlation with fasting glucose levels (r = -0.222, P = 0.023). A multivariable logistic regression showed that serum adropin was a significant predictor of positive IBD status when enumerated along with baseline characteristics (OR 0.455, 95% CI 0.251-0.823, P = 0.009). Our findings imply that adropin could be involved in complex pathophysiology of IBD, but further larger scale studies are needed to address these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.